Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 21 results.
User Information
Export Records
  1. 1.   Structure of Helicobacter pylori dihydroneopterin aldolase suggests a fragment-based strategy for isozyme-specific inhibitor design
  2. Shaw,Gary; Fan,Lixin; Cherry,Scott; Shi,Genbin; Tropea, Joseph E; Ji,Xinhua
  3. Current Research in Structural Biology. 2023, Jan 30; 5: 100095.
  1. 2.   Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
  2. Chae, Young K; Hong, Fangxin; Vaklavas, Christos; Cheng, Heather H; Hammerman, Peter; Mitchell, Edith P; Zwiebel, James A; Ivy, S Percy; Gray, Robert J; Li, Shuli; McShane, Lisa M; Rubinstein, Larry V; Patton, David; Williams,Mickey; Hamilton, Stanley R; Mansfield, Aaron; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T
  3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020, JUL 20; 38(21): 2407-+.
  1. 3.   PI3K inhibitors: review and new strategies
  2. Zhang,Mingzhen; Jang,Hyunbum; Nussinov,Ruth
  3. CHEMICAL SCIENCE. 2020, JUN 21; 11(23): 5855-5865.
  1. 4.   Report on the 2018 Cancer, Autoimmunity, and Immunology Conference
  2. Curran, Colleen S.; Sommers, Connie L.; Young,Howard; Bourcier, Katarzyna; Mancini, Marie; Sharon, Elad
  3. Journal of immunology (Baltimore, Md. : 1950). 2019, May 15; 202(10): 2823-2828.
  1. 5.   Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention
  2. Walter, Katherine R; Ford, Marvella E; Gregoski, Mathew J; Kramer, Rita M; Knight, Kendrea D; Spruill, Laura; Nogueira, Lourdes M; Krisanits, Bradley A; Phan, Van; La Rue, Amanda C; Lilly, Michael B; Ambs, Stefan; Chan,King; Turner, Tonya F; Varner, Heidi; Singh, Shweta; Uribarri, Jaime; Garrett-Mayer, Elizabeth; Armeson, Kent E; Hilton, Ebony J; Clair, Mark J; Taylor, Marian H; Abbott, Andrea M; Findlay, Victoria J; Peterson, Lindsay L; Magwood, Gayenell; Turner, David P
  3. Breast cancer research and treatment. 2019, Feb; 173(3): 559-571.
  1. 6.   Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF beta, in Advanced Solid Tumors
  2. Strauss, Julius; Heery, Christopher R.; Schlom, Jeffrey; Madan, Ravi A.; Cao, Liang; Kang, Zhigang; Lamping, Elizabeth; Marte, Jennifer L.; Donahue, Renee N.; Grenga, Italia; Cordes, Lisa; Christensen, Olaf; Mahnke, Lisa; Helwig, Christoph; Gulley, James L.
  3. Clinical Cancer Research. 2018, Mar 15; 24(6): 1287-1295.
  1. 7.   Immunological monitoring of the tumor immunoenvironment for clinical trials
  2. Malyguine, A. M.; Strobl, S. L.; Shurin, M. R.
  3. Cancer Immunology Immunotherapy. 2012, Feb; 61(2): 239-247.
  1. 8.   Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
  2. Kummar, S.; Chen, A.; Ji, J. P.; Zhang, Y. P.; Reid, J. M.; Ames, M.; Jia, L.; Weil, M.; Speranza, G.; Murgo, A. J.; Kinders, R.; Wang, L. H.; Parchment, R. E.; Carter, J.; Stotler, H.; Rubinstein, L.; Hollingshead, M.; Melillo, G.; Pommier, Y.; Bonner, W.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Cancer Research. 2011, Sep; 71(17): 5626-5634.
  1. 9.   Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
  2. Libutti, S. K.; Paciotti, G. F.; Byrnes, A. A.; Alexander, H. R.; Gannon, W. E.; Walker, M.; Seidel, G. D.; Yuldasheva, N.; Tamarkin, L.
  3. Clinical Cancer Research. 2010, Dec; 16(24): 6139-6149.
  1. 10.   The statistics of phase 0 trials
  2. Rubinstein, L. V.; Steinberg, S. M.; Kummar, S.; Kinders, R.; Parchment, R. E.; Murgo, A. J.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Statistics in Medicine. 2010, May; 29(10): 1072-1076.
  1. 11.   Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
  2. Bates, S. E.; Zhan, Z. R.; Steadman, K.; Obrzut, T.; Luchenko, V.; Frye, R.; Robey, R. W.; Turner, M.; Gardner, E. R.; Figg, W. D.; Steinberg, S. M.; Ling, A.; Fojo, T.; To, K. W.; Piekarz, R. L.
  3. British Journal of Haematology. 2010, Jan; 148(2): 256-267.
  1. 12.   Recent Development of Cyclic Amide (Pyridone/Lactam) Moiety Containing Heterocycles as Protein Kinase Inhibitors
  2. Wei, L. Y.; Malhotra, S. V.
  3. Current Medicinal Chemistry. 2010, Jan; 17(3): 234-253.
  1. 13.   Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer
  2. Matthews, K.; Noker, P. E.; Tian, B. H.; Grimes, S. D.; Fulton, R.; Schweikart, K.; Harris, R.; Aurigemma, R.; Wang, M. H.; Barnes, M. N.; Siegal, G. P.; Hemminki, A.; Zinn, K.; Curiel, D. T.; Alvarez, R. D.
  3. Clinical Cancer Research. 2009 15(12): 4131-4137.
  1. 14.   High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems
  2. Manimala, J. C.; Roach, T. A.; Li, Z. T.; Gildersleeve, J. C.
  3. Glycobiology. 2007, Aug; 17(8): 17C-23C.
  1. 15.   Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts
  2. Papadopoulou, M. V.; Bloomer, W. D.; Taylor, A. P.; Hernandez, M.; Blumenthal, R. D.; Hollingshead, M. G.
  3. Radiation Research. 2007, Jul; 168(1): 65-71.
  1. 16.   Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Delta 24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer
  2. Page, J. G.; Tian, B. H.; Schweikart, K.; Tomaszewski, J.; Harris, R.; Broadt, T.; Polley-Nelson, J.; Noker, P. E.; Wang, M. H.; Makhija, S.; Aurigemma, R.; Curiel, D. T.; Alvarez, R. D.
  3. American Journal of Obstetrics and Gynecology. 2007, Apr; 196(4):
  1. 17.   Structure-based discovery of a boronic acid bioisostere of combretastatin A-4
  2. Kong, Y.; Grembecka, J.; Edler, M. C.; Hamel, E.; Mooberry, S. L.; Sabat, M.; Rieger, J.; Brown, M. L.
  3. Chemistry & Biology. 2005, SEP; 12(9): 1007-1014.
  1. 18.   Tumour stem cells and drug resistance
  2. Dean, M.; Fojo, T.; Bates, S.
  3. Nature Reviews Cancer. 2005 5(4): 275-284.
  1. 19.   Increasing CD4(+) T cells specific for tuberculosis correlate with improved clinical immunity after highly active antiretroviral therapy
  2. Hengel, R. L.; Allende, M. C.; Dewar, R. L.; Metcalf, J. A.; Mican, J. M.; Lane, H. C.
  3. Aids Research and Human Retroviruses. 2002 18(13): 969-975.
  1. 20.   Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin
  2. Miller, L. L.; Korn, E. L.; Stevens, D. S.; Janik, J. E.; Gause, B. L.; Kopp, W. C.; Holmlund, J. T.; Curti, B. D.; Sznol, M.; Smith, J. W.; Urba, W. J.; Donegan, S. E.; Watson, T. M.; Longo, D. L.
  3. Blood. 1999 93(10): 3250-3258.
  1. 21.   Airway Cells 3D Reconstruction via Manual and Machine-Learning Aided Segmentation of Volume EM Datasets
  2. Vijayakumaran, Aaran; Abuammar, Analle; Medagedara, Odara; Narayan,Kedar; Mennella, Vito
  3. Methods in Molecular Biology (Clifton, N.J.). 2024 2725: 131-146.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel